NanoViricides - NNVC Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoViricides in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NNVC shares.
View NNVC analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 12 month target prices for NanoViricides' stock. Their NNVC share price forecasts range from $5.25 to $5.25. On average, they predict the company's share price to reach $5.25 in the next year. This suggests a possible upside of 318.0% from the stock's current price.
View analysts price targets for NNVC or view top-rated stocks among Wall Street analysts.

NanoViricides saw a increase in short interest in March. As of March 15th, there was short interest totaling 183,800 shares, an increase of 103.5% from the February 28th total of 90,300 shares. Based on an average daily volume of 28,500 shares, the days-to-cover ratio is currently 6.4 days. Approximately 1.7% of the company's shares are sold short.
View NanoViricides' Short Interest.

NanoViricides, Inc. (NYSEAMERICAN:NNVC) announced its quarterly earnings results on Tuesday, February, 14th. The company reported ($0.15) EPS for the quarter.

NanoViricides's stock reverse split on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), Inovio Pharmaceuticals (INO), Micron Technology (MU), Gilead Sciences (GILD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), iBio (IBIO) and Moderna (MRNA).

NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."

NanoViricides' stock is owned by many different institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.58%), Susquehanna International Group LLP (0.00%), Simplex Trading LLC (0.00%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.

Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NNVC stock can currently be purchased for approximately $1.26.

NanoViricides (NYSEAMERICAN:NNVC) has a market capitalization of $14.58 million. The company earns $-8,110,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The official website for the company is www.nanoviricides.com. The company can be reached via phone at (203) 937-6137, via email at info@nanoviricides.com, or via fax at 203-859-5095.